DTI-GP: Bayesian operations for drug-target interactions using deep kernel Gaussian processes
By: Bence Bolgár, András Millinghoffer, Péter Antal
Potential Business Impact:
Finds best medicines using smart computer guesses.
Precise probabilistic information about drug-target interaction (DTI) predictions is vital for understanding limitations and boosting predictive performance. Gaussian processes (GP) offer a scalable framework to integrate state-of-the-art DTI representations and Bayesian inference, enabling novel operations, such as Bayesian classification with rejection, top-$K$ selection, and ranking. We propose a deep kernel learning-based GP architecture (DTI-GP), which incorporates a combined neural embedding module for chemical compounds and protein targets, and a GP module. The workflow continues with sampling from the predictive distribution to estimate a Bayesian precedence matrix, which is used in fast and accurate selection and ranking operations. DTI-GP outperforms state-of-the-art solutions, and it allows (1) the construction of a Bayesian accuracy-confidence enrichment score, (2) rejection schemes for improved enrichment, and (3) estimation and search for top-$K$ selections and ranking with high expected utility.
Similar Papers
Deep Gaussian Processes with Gradients
Methodology
Helps computers learn from data with tricky shapes.
Heterogeneous network drug-target interaction prediction model based on graph wavelet transform and multi-level contrastive learning
Quantitative Methods
Finds new medicines by understanding how they work.
Structure-Aware Contrastive Learning with Fine-Grained Binding Representations for Drug Discovery
Machine Learning (CS)
Finds new medicines faster by looking at how they fit.